FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study

FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study | PharmExec — Pharmexec

FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study | PharmExec